Ariad plans to file NDA in 3rd quarter of 2016

Ariad plans to file a new drug application (NDA) for brigatnib in 3rd quarter of 2016.

http://investor.ariad.com/mobile.view?c=118422&v=203&d=1&id=2075920

This entry was posted in AP26113 - brigatinib from Ariad, Brain metastases, Lung cancer, Potential Treatments, Regulatory applications & approvals. Bookmark the permalink.

Leave a Reply